MedTrace Logo

Clinical Trials

NCT04314401 | ACTIVE_NOT_RECRUITING
1600 participants

National Cancer Institute "Cancer Moonshot Biobank"

Study Type:
OBSERVATIONAL
Last Updated:
2026-05-13
Start Date:
2020-11-11
Completion:
2027-04-30
Conditions
  • Acute Myeloid Leukemia
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Esophageal Carcinoma
  • Fallopian Tube Carcinoma
  • Gastric Carcinoma
  • Hormone Receptor-Positive Breast Carcinoma
  • Invasive Breast Carcinoma
  • Lung Non-Small Cell Carcinoma
  • Lung Small Cell Carcinoma
  • Malignant Solid Neoplasm
  • Melanoma
  • Metastatic Prostate Carcinoma
  • Multiple Myeloma
  • Ovarian Carcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal Carcinoma
  • Stage III Fallopian Tube Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Fallopian Tube Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8
  • Triple-Negative Breast Carcinoma
Interventions
  • PROCEDURE
  • OTHER
No Results Yet
NCT04214067 | ACTIVE_NOT_RECRUITING | PHASE3
164 participants

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-04-09
Completion:
2025-12-30
Conditions
  • Endometrial Endometrioid Adenocarcinoma
  • Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
  • PROCEDURE
  • RADIATION
  • BIOLOGICAL
  • OTHER
No Results Yet
NCT04210115 | ACTIVE_NOT_RECRUITING | PHASE3
703 participants

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-02-28
Completion:
2026-01-21
Conditions
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Gastroesophageal Junction Carcinoma (GEJC)
  • Esophageal Adenocarcinoma (EAC)
Interventions
  • BIOLOGICAL
  • DRUG
  • RADIATION
No Results Yet
NCT04165096 | COMPLETED | PHASE2
128 participants

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-01-21
Completion:
2025-04-30
Conditions
  • Carcinoma, Non-Small-Cell Lung
Interventions
  • BIOLOGICAL
  • DRUG
Results Available
NCT04164082 | ACTIVE_NOT_RECRUITING | PHASE2
161 participants

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-03-18
Completion:
2026-12-09
Conditions
  • Bladder Flat Urothelial Carcinoma In Situ
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Stage 0a Bladder Cancer AJCC v8
  • Stage 0is Bladder Cancer AJCC v8
  • Stage I Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04092270 | ACTIVE_NOT_RECRUITING | PHASE1
54 participants

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-05-07
Completion:
2026-06-01
Conditions
  • Endometrial High Grade Endometrioid Adenocarcinoma
  • Fallopian Tube Clear Cell Adenocarcinoma
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
  • Fallopian Tube Mucinous Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fallopian Tube Undifferentiated Carcinoma
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Ovarian Undifferentiated Carcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Primary Peritoneal Carcinosarcoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Primary Peritoneal Transitional Cell Carcinoma
  • Primary Peritoneal Undifferentiated Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor
  • Recurrent Ovarian Mucinous Adenocarcinoma
  • Recurrent Ovarian Transitional Cell Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04090398 | ACTIVE_NOT_RECRUITING | PHASE2
70 participants

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-08-04
Completion:
2026-06-30
Conditions
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
  • RADIATION
No Results Yet
NCT04071236 | RECRUITING | PHASE1/PHASE2
90 participants

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-10-14
Completion:
2027-04-30
Conditions
  • Metastatic Castration-Resistant Prostate Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
  • Metastatic Malignant Neoplasm in the Lymph Nodes
  • Stage IVB Prostate Cancer AJCC v8
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • RADIATION
No Results Yet
NCT04071223 | ACTIVE_NOT_RECRUITING | PHASE2
134 participants

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-07-29
Completion:
2026-10-01
Conditions
  • Advanced Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Kidney Medullary Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
  • Papillary Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8
  • Unclassified Renal Cell Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • RADIATION
No Results Yet
NCT04068194 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
103 participants

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-04-07
Completion:
2027-07-01
Conditions
  • Locally Advanced Malignant Solid Neoplasm
  • Locally Advanced Unresectable Cholangiocarcinoma
  • Locally Advanced Unresectable Gallbladder Carcinoma
  • Locally Advanced Unresectable Malignant Solid Neoplasm
  • Metastatic Cholangiocarcinoma
  • Metastatic Gallbladder Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Stage III Gallbladder Cancer AJCC v8
  • Stage IV Gallbladder Cancer AJCC v8
  • Unresectable Malignant Solid Neoplasm
Interventions
  • DRUG
  • PROCEDURE
  • RADIATION
No Results Yet
NCT04067336 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
263 participants

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2019-09-12
Completion:
2028-10-16
Conditions
  • Advanced Malignant Neoplasm
  • Acute Myeloid Leukemia
  • Mixed Lineage Leukemia
  • Mixed Lineage Acute Leukemia
  • Acute Leukemia of Ambiguous Lineage
  • Mixed Phenotype Acute Leukemia
  • Acute Lymphoblastic Leukemia
Interventions
  • DRUG
No Results Yet
NCT04052555 | ACTIVE_NOT_RECRUITING | PHASE1
42 participants

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2020-09-24
Completion:
2027-02-24
Conditions
  • Bilateral Breast Carcinoma
  • HER2-Negative Breast Carcinoma
  • Localized Breast Carcinoma
  • Recurrent Breast Carcinoma
  • Triple-Negative Breast Carcinoma
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • RADIATION
No Results Yet
NCT03816358 | ACTIVE_NOT_RECRUITING | PHASE1
74 participants

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-13
Start Date:
2019-12-09
Completion:
2027-01-31
Conditions
  • Pancreatic Adenocarcinoma
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page